Downstaging and Histological Effects Might Be Reliable Predictors of the Efficacy of DOC+CDDP+5-FU (DCF) as Neoadjuvant Therapy for Stage III or Borderline Resectable Esophageal Cancer: a Single Institute Experience.
Kazuma KobayashiKengo KanetakaAkira YonedaShinichiro KobayashiYasuhiro MaruyaYuriko IsagawaTomoko YoshimotoKazushige MigitaYuta KawaguchiSayaka KubaMichi MoritaSatomi OkadaTaiichiro KosakaShun YamaguchiYusuke InoueTomohiko AdachiMasaaki HidakaYasuhiro TorashimaShinichiro ItoMitsuhisa TakatsukiSusumu EguchiPublished in: Journal of gastrointestinal cancer (2021)
DCF therapy for stage ≥ III esophageal carcinoma is both feasible and effective. These findings suggest that downstaging and the histological effect might predict the effects of DCF therapy for EC.